依鲁替尼联合度伐利尤单抗治疗复发或难治性滤泡性淋巴瘤或弥漫性大B细胞淋巴瘤的安全性与活性
这项1b/2期多中心开放标签研究评估了依鲁替尼联合度伐利尤单抗在复发/难治性滤泡性淋巴瘤(FL)或弥漫性大B细胞淋巴瘤(DLBCL)中的安全性和活性。61例患者接受依鲁替尼560mg每日一次联合度伐利尤单抗10mg/kg每2周方案,总体缓解率(ORR)为25%,FL为26%,GCB DLBCL为13%,非GCB DLBCL为38%;中位无进展生存期4.6个月,中位总生存期18.1个月。联合方案的安全性特征与各单药已知安全性基本一致,但增加了PD-L1阻断相关毒性。
要点
- 依鲁替尼联合度伐利尤单抗在复发/难治FL和DLBCL中总体ORR为25%。
- FL患者中位PFS和OS均长于DLBCL患者。
- 联合方案活性与单药依鲁替尼相似,但增加了PD-L1阻断相关毒性。
核心结论
- 在FL、GCB DLBCL和非GCB DLBCL中,依鲁替尼联合度伐利尤单抗的活性与单药依鲁替尼相似,但增加了PD-L1阻断相关毒性。
研究设计与样本
- 1b/2期多中心开放标签研究,评估依鲁替尼联合度伐利尤单抗治疗复发/难治性FL或DLBCL。
- 1b期采用依鲁替尼560mg每日一次联合度伐利尤单抗10mg/kg每2周(28天周期),未出现剂量限制性毒性,确认2期剂量。
- 共治疗61例患者:FL 27例,GCB DLBCL 16例,非GCB DLBCL 16例,未指定DLBCL 2例。
主要发现
- 总体缓解率(ORR)在所有患者中为25%,FL为26%,GCB DLBCL为13%,非GCB DLBCL为38%。
- 总体中位无进展生存期为4.6个月,中位总生存期为18.1个月;两者在FL患者中均长于DLBCL患者。
- FL和DLBCL患者中最常见的治疗中出现的不良事件(AE)分别包括腹泻(16例[59%];16例[47%])、疲乏(12例[44%];16例[47%])、恶心(9例[33%];12例[35%])、外周水肿(7例[26%];13例[38%])、食欲下降(8例[30%];11例[32%])、中性粒细胞减少(6例[22%];11例[32%])和呕吐(5例[19%];12例[35%])。
- 研究者定义的免疫相关AE发生于12/61(20%)患者。
- 相关性分析未识别出任何确切的疗效生物标志物。
关键数值与推荐
- 依鲁替尼560mg每日一次联合度伐利尤单抗10mg/kg每2周,28天为一周期。
- 总体ORR 25%,FL 26%,GCB DLBCL 13%,非GCB DLBCL 38%。
- 中位PFS 4.6个月,中位OS 18.1个月。
临床怎么用
- 该联合方案在复发/难治FL和DLBCL中显示出一定活性,但并未明显优于单药依鲁替尼,且增加免疫相关毒性。
- 临床决策需权衡联合方案的额外毒性与其有限的疗效增益。
局限性
- 研究为1b/2期开放标签设计,样本量有限(61例),各亚组例数较少。
- 相关性分析未识别出确切的疗效生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase 1b/2, multicenter, open-label study evaluated ibrutinib plus durvalumab in relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). Patients were treated with once-daily ibrutinib 560 mg plus durvalumab 10 mg/kg every 2 weeks in 28-day cycles in phase 1b without dose-limiting toxicities, confirming the phase 2 dosing. Sixty-one patients with FL (n = 27), germinal center B-cell (GCB) DLBCL (n = 16), non-GCB DLBCL (n = 16), and unspecified DLBCL (n = 2) were treated. Overall response rate (ORR) was 25% in all patients, 26% in patients with FL, 13% in patients with GCB DLBCL, and 38% in patients with non-GCB DLBCL. Overall, median progression-free survival was 4.6 months and median overall survival was 18.1 months; both were longer in patients with FL than in patients with DLBCL. The most frequent treatment-emergent adverse events (AEs) in patients with FL and DLBCL, respectively, were diarrhea (16 [59%]; 16 [47%]), fatigue (12 [44%]; 16 [47%]), nausea (9 [33%]; 12 [35%]), peripheral edema (7 [26%]; 13 [38%]), decreased appetite (8 [30%]; 11 [32%]), neutropenia (6 [22%]; 11 [32%]), and vomiting (5 [19%]; 12 [35%]). Investigator-defined immune-related AEs were reported in 12/61 (20%) patients. Correlative analyses were conducted but did not identify any conclusive biomarkers of response. In FL, GCB DLBCL, and non-GCB DLBCL, ibrutinib plus durvalumab demonstrated similar activity to single-agent ibrutinib with the added toxicity of the PD-L1 blockade; the combination resulted in a safety profile generally consistent with those known for each individual agent.
引用
- Herrera AF, Goy A, Mehta A, et al. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. Am J Hematol. 2019. PMID: 31621094. doi:10.1002/ajh.25659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。